MHRA Chief On How The UK Agency Is Overhauling Its Processes To Overcome Post-Brexit Challenges
The Medicines and Healthcare products Regulatory Agency has introduced a series of changes, including an upcoming overhaul of its clinical trial legislation, to enhance its performance in the future, chief executive Dame June Raine writes.
Dame June Raine, chief executive of the UK MHRA • Source: MHRA
There can be no doubt that recent years have signified a period of great change for the UK’s Medicines and Healthcare products Regulatory Agency (MHRA), as highlighted in the recent LifeArc conference.
About The Author
Dame June Raine is the chief executive of the Medicines and Healthcare products Regulatory Agency.
